このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Avenue Therapeutics 将来の成長

Future 基準チェック /06

Avenue Therapeuticsは、13.4%と90.5%でそれぞれ年率13.4%で利益と収益が成長すると予測される一方、EPSはgrowで58.9%年率。

主要情報

13.4%

収益成長率

58.9%

EPS成長率

Pharmaceuticals 収益成長	27.3%
収益成長率	90.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 Jun 2024

今後の成長に関する最新情報

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

業績と収益の成長予測

NasdaqCM:ATXI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-17	N/A	N/A	1
12/31/2025	N/A	-15	N/A	N/A	1
12/31/2024	N/A	-14	N/A	N/A	1
3/31/2024	N/A	-7	-14	-11	N/A
12/31/2023	N/A	-10	-12	-9	N/A
9/30/2023	N/A	-10	-14	-11	N/A
6/30/2023	N/A	-12	-13	-11	N/A
3/31/2023	N/A	-8	-7	-7	N/A
12/31/2022	N/A	-4	-8	-8	N/A
9/30/2022	N/A	-5	-5	-5	N/A
6/30/2022	N/A	-5	-5	-5	N/A
3/31/2022	N/A	-6	-4	-4	N/A
12/31/2021	N/A	-4	-4	-4	N/A
9/30/2021	N/A	-4	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-5	-5	N/A
9/30/2020	N/A	-10	-8	-8	N/A
6/30/2020	N/A	-11	-9	-9	N/A
3/31/2020	N/A	-16	-22	-22	N/A
12/31/2019	N/A	-26	-26	-26	N/A
9/30/2019	N/A	-24	-23	-23	N/A
6/30/2019	N/A	-25	-25	-25	N/A
3/31/2019	N/A	-22	-17	-17	N/A
12/31/2018	N/A	-22	-18	-18	N/A
9/30/2018	N/A	-24	-21	-21	N/A
6/30/2018	N/A	-24	-19	-19	N/A
3/31/2018	N/A	-22	-14	-14	N/A
12/31/2017	N/A	-12	N/A	-7	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-1	N/A
3/31/2017	N/A	-3	N/A	-1	N/A
12/31/2016	N/A	-3	N/A	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATXI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATXI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ATXI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATXI来年は収益がないと予測されています。

高い収益成長: ATXI来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATXIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Avenue Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 1,500% to US$900

Forecast breakeven pushed back to 2024

Price target lowered to US$9.00

Recent updates

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘